Sugi Predict

Sugi Predict / Compounds / SCHEMBL13924582

SCHEMBL13924582

SCHEMBL13924582

CN(C)CCCC(=O)Nc1cccc(Nc2nccc(-c3nccs3)n2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 11/20 0.58
▸ SRC P12931 5/20 0.58
▸ ZAP70 P43403 3/20 0.58
▸ CDK2 P24941 1/20 0.58
▸ ABL1 P00519 3/20 0.55
▸ PDGFRB P09619 2/20 0.55
▸ PDGFRA P16234 2/20 0.55
▸ PRKCA P17252 1/20 0.55
▸ PRKCD Q05655 1/20 0.55
▸ BCR P11274 1/20 0.54
▸ JAK2 O60674 2/20 0.52
▸ HDAC1 Q13547 2/20 0.52
▸ HDAC6 Q9UBN7 2/20 0.52
▸ EGFR P00533 2/20 0.49
▸ CCNT1 O60563 1/20 0.49
▸ CDK9 P50750 1/20 0.49
▸ ERBB2 P04626 1/20 0.47
▸ IGF1R P08069 1/20 0.47
▸ PTK2 Q05397 1/20 0.47
▸ CDK19 Q9BWU1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13924590 0.84 SYK (0.57) SYKSRCZAP70CDK2ABL1
SCHEMBL13924587 0.84 SYK (0.58) SYKSRCZAP70CDK2ABL1
SCHEMBL13924585 0.83 SYK (0.50) SYKSRCZAP70CDK2ABL1
SCHEMBL13924583 0.82 JAK2 (0.52) SYKSRCZAP70CDK2ABL1
SCHEMBL13924588 0.81 SYK (0.51) SYKSRCZAP70CDK2ABL1
SCHEMBL13924591 0.80 SYK (0.55) SYKSRCZAP70CDK2ABL1
SCHEMBL13924589 0.79 SYK (0.57) SYKSRCZAP70CDK2ABL1
SCHEMBL13924586 0.79 SYK (0.48) SYKSRCZAP70CDK2ABL1
SCHEMBL14224137 0.78 ABL1 (0.66) SRCABL1PDGFRBPDGFRAPRKCA
SCHEMBL13924606 0.78 SYK (0.68) SYKSRCZAP70CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7488727-B2 Thiazole compounds useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-02-10 — — US disclosed
US-7488727-B2 Thiazole compounds useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-02-10 — — US disclosed
US-20070249645-A1 THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED 2007-10-25 — — US disclosed
US-20070249645-A1 THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASE VERTEX PHARMACEUTICALS INCORPORATED 2007-10-25 — — US disclosed
US-7256190-B2 Thiazole compounds useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-14 — — US disclosed
US-7256190-B2 Thiazole compounds useful as inhibitors of protein kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249645-A1 THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASE BTK, AURKC, GSK3B SYK 5/4885SRC 64/4885ZAP70 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.